Leading Firms Reshaping the Future of Monkeypox Testing Market
The global monkeypox
testing market is experiencing notable expansion, driven by the
increasing incidence of monkeypox cases worldwide and the imperative for prompt
and accurate diagnostic solutions.
According to the research
report, the global monkeypox testing market was valued at USD 1,331.48 million
in 2021 and is expected to reach USD 1,968.47 million by 2030, to grow at a
CAGR of 4.5% during the forecast period.
Market Overview
Monkeypox, a zoonotic viral
disease akin to smallpox, has garnered global attention due to recent outbreaks
beyond its traditional endemic regions. The surge in cases has underscored
the critical need for reliable and swift diagnostic methods to facilitate early
detection, patient management, and containment of the virus's spread. Consequently,
the demand for monkeypox testing has escalated, propelling market growth.
Market Segmentation
The monkeypox testing market
is segmented based on technology, mode of testing, end-use, and region:
- By
Technology:
- Polymerase Chain Reaction (PCR): Dominating the market with a 60% share
in 2023, PCR is esteemed for its high sensitivity and specificity in
detecting viral DNA, making it the gold standard for monkeypox diagnosis.
- Lateral Flow Assay (LFA): Recognized for rapid results and
user-friendliness, LFA is gaining traction, particularly in point-of-care
settings.Other Technologies: Encompassing emerging
diagnostic methods under development to enhance detection accuracy and
speed.
- By
Mode of Testing:
- Laboratory Testing: Accounting for USD 1.1 billion in 2023,
laboratory testing offers comprehensive analysis and is integral to
large-scale diagnostic operations.
- Point-of-Care Testing: Valued for delivering immediate results,
facilitating prompt clinical decisions, and improving patient outcomes.
- By
End-Use:
- Hospitals and Clinics: Representing 50% of the market share in
2023, these facilities are primary venues for patient diagnosis and care.
- Diagnostic Laboratories: Projected to experience the fastest
growth, driven by the escalating demand for specialized testing services.
- Other End Users: Including research institutions and
public health agencies engaged in surveillance and epidemiological
studies.
Regional Analysis
The market's regional
dynamics are influenced by the prevalence of monkeypox cases, healthcare
infrastructure, and governmental initiatives:
- North
America: Leading the market with a 45%
revenue share in 2023, the region's advanced healthcare systems and
proactive public health measures have facilitated extensive testing
capabilities. The United States, in particular, has reported
significant case numbers, prompting robust diagnostic responses.
- Europe: Accounting for 20% of the market revenue
in 2023, European countries have prioritized standardizing testing
protocols and expanding molecular diagnostic capacities in response to outbreaks. Spain
and Germany have been notably proactive, implementing comprehensive
testing and vaccination strategies.
- Asia-Pacific: Holding a 25% market share in 2023, the
region is anticipated to witness the highest CAGR, driven by improving
healthcare infrastructure and heightened awareness in nations such as
Japan, China, and India. Japan is expected to register the highest
growth rate from 2024 to 2030.
- Latin
America and Middle East & Africa: Each
contributing 5% to the market in 2023, these regions face challenges
related to limited testing accessibility and infrastructure. However,
initiatives like Morocco's production of affordable mpox tests aim to
enhance diagnostic capabilities and reduce reliance on imports.
Explore More:
https://www.polarismarketresearch.com/industry-analysis/monkeypox-testing-market
Key Market Drivers
- Rising
Incidence of Monkeypox Cases: The
global upsurge in monkeypox infections has necessitated widespread testing
to enable early detection and containment.
- Advancements
in Diagnostic Technologies: Innovations
in molecular diagnostics, particularly PCR and rapid antigen tests, have
improved the accuracy and efficiency of monkeypox detection.
- Governmental
and Health Organization Initiatives: Collaborative
efforts by governments and international health bodies have focused on
enhancing testing capacities, public awareness, and vaccine distribution
to curb the virus's spread.
Key Companies in the Monkeypox
Testing Market
The market features several
prominent players dedicated to advancing diagnostic solutions:
- Aegis Sciences Corp
- BD
- Chembio Diagnostics Inc.
- Laboratory Corp. of America Holdings
- Mayo Clinic Laboratories
- QIAGEN
- Quest Diagnostics Inc
- Sonia Healthcare Ltd
- Sonora Quest Laboratories
- Thermo Fisher Scientific
More Trending Latest Reports By Polaris Market
Research:
Healthcare
Cybersecurity Market
Acute
Lymphocytic/Lymphoblastic Leukemia Therapeutics Market
Medical
Imaging Equipment Market
Healthcare Bioconvergence
Market
Oligonucleotide
Synthesis Market
Comments
Post a Comment